Reimagining cell therapy.
Founded in 2015, Arcellx engineers innovative immunotherapies using its proprietary ARC-SparX platform to develop safer, more effective cell therapies. The company focuses on hematologic cancers and autoimmune conditions, with programs in multiple myeloma and other indications.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account